OVERVIEW

Progress in Idiopathic Pulmonary Fibrosis: Strategies to Speed Detection and Slow Progression is organized by Paradigm Medical Communications, LLC and will be held from Jul 17, 2018 - Jul 17, 2019. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits.

Target Audience:
This activity has been designed to address the educational needs of community-based pulmonologists. It may also be of benefit to other pulmonologists who are not affiliated with an interstitial lung disease (ILD) center, as well as radiologists, pathologists, primary care physicians, nurse practitioners, PAs, pharmacists, nurses, residents, fellows, and other clinicians involved in the treatment of patients with interstitial lung diseases including idiopathic pulmonary fibrosis (IPF).

Statement of Need:
Idiopathic pulmonary fibrosis (IPF)-a fatal and relentlessly progressive fibrosing interstitial lung disease (ILD)-presents diagnostic challenges for pulmonologists, who must assess vague symptoms and rule out more than 100 other potential ILDs and non-ILD mimickers via scrupulous testing and multidisciplinary collaboration. Early detection has become more critical than ever, with the US Food and Drug Administration’s (FDA) first-ever approval of IPF treatments (antifibrotics) in October 2014. While these agents offer pulmonologists an unprecedented opportunity to slow IPF disease progression, data show that these clinicians, who are integral to IPF care, remain unfamiliar with many practical aspects of antifibrotic use, including when to start prescribing them.

Learning Objectives:
Upon proper completion of this activity, participants should be better able to:
• Evaluate patients with symptoms of interstitial lung disease according to guideline-based algorithms to correctly identify idiopathic pulmonary fibrosis.
• Individualize antifibrotic therapy for appropriate patients with idiopathic pulmonary fibrosis, based on current evidence.
• Outline evidence-based information about idiopathic pulmonary fibrosis disease course and treatment to share with patients at the time of diagnosis.

Additional details will be posted as soon as they are available.